Trial Profile
Intercalated Combination of Chemotherapy Plus Icotinib for Patients Undergoing Resection of EGRF Mutation-positive Non-small-cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Oct 2014 New trial record